SCHEMBL1738367

SCHEMBL1738367

C=CCc1ccc(Br)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
PPARG P37231 2/20 0.47
PPARD Q03181 2/20 0.47
PPARA Q07869 1/20 0.47
XDH P47989 1/20 0.47
MAPT P10636 5/20 0.46
GABRA1 P14867 4/20 0.46
GABRB2 P47870 4/20 0.46
MEN1 O00255 3/20 0.46
GAA P10253 3/20 0.46
CNR2 P34972 3/20 0.46
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 2/20 0.46
CNR1 P21554 2/20 0.46
HPGD P15428 2/20 0.46
ALDH2 P05091 1/20 0.46
AKR1B1 P15121 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALOX5 P09917 4/20 0.43
CYP3A4 P08684 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2723303 0.82 ALDH1A1 (0.37) ALDH1A1MAPTMEN1GAAKMT2A
SCHEMBL1734236 0.81 XDH (0.52) ALDH1A1PPARGPPARDPPARAXDH
SCHEMBL1733361 0.81 XDH (0.52) ALDH1A1PPARGPPARDPPARAXDH
SCHEMBL26170093 0.80 SKP2 (0.52) ALDH1A1PPARGPPARDPPARAXDH
SCHEMBL11194769 0.78 ALDH1A1 (0.48) ALDH1A1PPARGPPARDPPARAXDH
SCHEMBL10773338 0.77 ALDH1A1 (0.44) ALDH1A1PPARGPPARDPPARAXDH
SCHEMBL27258973 0.77 PKM (0.36) ALDH1A1MAPTMEN1GAAKMT2A
SCHEMBL15262300 0.77 FFAR4 (0.41) ALDH1A1PPARGPPARDPPARAXDH
SCHEMBL2295101 0.76 XDH (0.47) ALDH1A1PPARGPPARDPPARAXDH
SCHEMBL2297312 0.76 XDH (0.47) ALDH1A1PPARGPPARDPPARAXDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
EP-2390252-A1 New pyrazole derivatives Almirall, S.A. (ES) 2011-11-30 EP disclosed
WO-2011144338-A1 PYRAZOLE DERIVATIVES AS S1P1 AGONISTS ALMIRALL, S.A. (ES) 2011-11-24 WO disclosed
EP-2370431-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE Almirall S.A. (ES) 2011-10-05 EP disclosed
WO-2010072352-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE S1PR1, S1PR2, S1PR3 ALDH1A1 1042/4885PPARG 593/4885PPARD 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.